PRDM16s将巨核-红系祖细胞转化为髓系白血病起始细胞
研究发现转录调节因子PRDM16s可使原本定向形成血小板和红细胞的巨核-红系祖细胞(MEP)转化为髓系白血病干细胞(LSC),从而引发急性髓系白血病(AML)。PRDM16s通过结合超级增强子并激活包括PU.1在内的髓系主调控因子,阻断巨核/红系潜能;CRISPR筛选证实PU.1是PRDM16s诱导白血病所必需,敲除PU.1可减弱白血病生成并恢复小鼠模型及PRDM16重排人AML中白血病性MEP的巨核/红系潜能。
要点
- PRDM16s在MEP中表达使其转化为LSC并引发AML。
- PRDM16s通过超级增强子激活PU.1等髓系主调控因子。
- 敲除PU.1可减弱白血病生成并恢复巨核/红系潜能。
核心结论
- 致癌性PRDM16s表达通过激活髓系基因调控网络赋予MEP以LSC命运。
研究设计与样本
- 研究采用小鼠模型及人AML样本,结合CRISPR dropout筛选。
主要发现
- Prdm16s在MEP中表达导致AML,将MEP转化为LSC。
- Prdm16s通过结合超级增强子并激活PU.1等髓系主调控因子,阻断巨核/红系潜能。
- CRISPR dropout筛选证实PU.1为Prdm16s诱导白血病所必需。
- 敲除PU.1可减弱白血病生成,并在小鼠模型及PRDM16重排人AML中恢复白血病性MEP的巨核/红系潜能。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Oncogenic mutations confer on cells the ability to propagate indefinitely, but whether oncogenes alter the cell fate of these cells is unknown. Here, we show that the transcriptional regulator PRDM16s causes oncogenic fate conversion by transforming cells fated to form platelets and erythrocytes into myeloid leukemia stem cells (LSCs). Prdm16s expression in megakaryocyte-erythroid progenitors (MEPs), which normally lack the potential to generate granulomonocytic cells, caused AML by converting MEPs into LSCs. Prdm16s blocked megakaryocytic/erythroid potential by interacting with super enhancers and activating myeloid master regulators, including PU.1. A CRISPR dropout screen confirmed that PU.1 is required for Prdm16s-induced leukemia. Ablating PU.1 attenuated leukemogenesis and reinstated the megakaryocytic/erythroid potential of leukemic MEPs in mouse models and human AML with PRDM16 rearrangement. Thus, oncogenic PRDM16 s expression gives MEPs an LSC fate by activating myeloid gene regulatory networks.
引用
- Hu T, Morita K, Hill MC, et al. PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia-initiating cells. Blood. 2019. PMID: 31270104. doi:10.1182/blood.2018888255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。